Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SWOG S2209
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- NCT05561387 ↗
- Recruiting
- SWOG Cancer Research Network
- Focused
We haven't built an HCP commentary report on SWOG S2209 (bortezomib, daratumumab and hyaluronidase-fihj and 2 more in Plasma Cell Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S2209 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib; Daratumumab and Hyaluronidase-fihj; Dexamethasone; Lenalidomide; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (VRd-Lite) · Active comparator
- Arm II (DRd-R) · Experimental
- Arm III (DRd-DR): · Experimental
- Enrollment
- 510 (estimated)
- Primary outcomes
- Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2
- Overall survival (OS) of Arm 1 vs. Arm 3
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Oct 12, 2023
- Primary completion
- May 30, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05561387 · updated Jun 10, 2026